ClinicalTrials.gg
Status unknownNCT04444271Updated Jun 30, 2020

Mesenchymal Stem Cell Infusion for COVID-19 Infection

A Phase 2 interventional study of Mesenchymal stem cells and Placebo in COVID-19, sponsored by Dr. Zaineb Akram. Status unknown at 1 site in Pakistan. Open to participants aged 10 Years and older. Per ClinicalTrials.gov, last updated 2020-06-30.

Sponsored by Dr. Zaineb Akram · Phase 2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jun 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
10 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 98 studies in COVID-19 with a site in Pakistan — 3 open to participants now, 4 under way, 2 of them phase 3. COVID-19 · Pakistan.

Planned enrollment
67th of 71
20 · median 125
Started
2020
with 61 others
Phase 2
7 of 98
1 open now
Registered
15th of 98
by date

Among the 98 studies in COVID-19 with a site in Pakistan, this one is the 67th largest by planned enrollment of the 71 interventional ones that give a count, is one of 62 that started in 2020, is one of 7 in phase 2, and was the 15th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

3 of the 98 studies in COVID-19 with a site in Pakistan are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 10 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in COVID-19 with a site in Pakistan, or all of them as a file.
02

Study summary

Since the outbreak of coronavirusdisease2019(COVID-19), many researchers in China have carried out/published clinical trials on treatment based on Western medicine, traditional Chinese medicine or a combination of the two. Trials on treatment modalities have mainly used antivirals, interferon, glucocorticoids in addition to traditional Chinese medicine. There are also clinical trials exploring hydroxyquinoline/chloroquine sulphate, immunoglobulins, Vitamin-C, washed microbiota, nebulized interferon, teicoplanin as well as Mesenchymal stem cells. However, most of these trials were small (median sample size 100) and the bulk of potential therapeutic strategies remain in the experimental phase and currently there is no effective specific antiviral with high-level evidence.The aim of this study is assess the efficacy of MSCs as an add-on therapy to standard supportive treatment for patients with moderate/severe COVID-19.

Read the detailed description

All patients will receive 2x10\^6 cells/kg on days 1 and day 7 (if needed). The study will be divided in 2 phases. In the first phase, 10 patients will be included and randomized to 2 groups (5 Treatment arm; 5 Control Arm) and receive 2 x10\^6 cells/kg MSCs on days 1 and 7 in addition to standard care. Thereafter, the trial committee will meet and evaluate all collected safety and efficacy information to decide about crossover of Control arm to treatment arm if patient deteriorates clinically while in Control arm. Then, 10 new subjects will be included in the study and treated according to protocol.

Preparation of MSCs doses MSCs will be isolated from bone marrow harvested cells. About 50ml bone marrow will be collected from iliac crest using aseptic technique in syringes primed with anticoagulant. The collected sample will be diluted with Phosphate Buffer Saline (PBS) and MSCs will be separated using density gradient centrifugation. After resuspension the cells will be seeded at a fixed concentration of 100,000 cells/cm2 in specially designed flasks and incubated at 37oC in 5% carbondioxide (CO2). Medium will be changed after every third day till harvesting of MSCs from the flasks. Once confluent (approximately day 20) the cells will be harvested with sterile techniques using Trypsin- Ethylenediaminetetraacetic acid ( EDTA ) solution. The prepared cells can either be stored in 50ml cryogenic vials for future use or infused immediately.

Patient Selection and MSCs demand Patient for MSCs and Control arm will be selected by multidisciplinary team (MDT) comprising Critical Care Specialist, Pulmonologist, Infectious Disease Specialist, Clinical Hematologist.

  1. Demand for MSCs will be initiated on pre-designated forms , signed by Critical care Specialist Clearly indicating indication of MSCs.
  2. Request form will be sent Stem Cell Lab.
  3. Incharge stem Cell Lab will authorize issuance of the MSCs dose.
  4. Stem Cell Lab will issue the dose Administration of MSCs
  1. Experimental arm: Frozen MSCs will be resuspended in 100ml normal saline for immediate use and given intravenously. The patients should be pre-medicated to avoid allergic reactions to third party MSCs. Each patient in Experimental arm will be given 2 x 106 cells/kg will be administered on day 1,7 in addition to supportive care 2. Control Arm: Will be Continued on supportive care

Proposed usage:

Because of the very limited availability of MSCs, their usage has to be rationalized by MDT comprising of pulmonologist, critical care specialist and clinical haematologist and Infectious disease specialist.There is not enough evidence to put forth therapeutic recommendations however, treatment decisions can be made on case to case basis after MDT.

03

Conditions studied

  • COVID-19

Keywords

  • Coronavirus
  • Mesenchymal Stem Cells
  • Survival
04

Who can participate

Ages eligible
10 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, aged ≥ 10years
  2. Laboratory confirmation of COVID19 infection by reverse-transcription polymerase chain reaction (RT-PCR) from any diagnostic sampling source; and
  3. Moderate illness: In compliance with the 2019-coronavirus pneumonia diagnosis standard [according to the novel coronavirus infection pneumonia diagnosis and treatment program (Trial Implementation Version 6) issued by the National Health and Medical Commission, and world health organization (WHO) 2019 new coronavirus guidelines standards]: (A) increased breathing rate (≥30 beats / min), difficulty breathing, cyanosis of the lips; (B) in resting state, means oxygen saturation ≤93%; (C) partial pressure of arterial oxygen (PaO2) / Fraction of inspired oxygen (FiO2) ≤300 mmHg (1mmHg = 0.133kPa);
  4. Critically ill : Respiratory failure, Septic Shock, muti-organ dysfunction syndrome (MODS)

Exclusion criteria

Exclusion Criteria:

  1. Patients with systemic diseases
  2. Not consenting for clinical trial
  3. Those declared not for resuscitation due to underlying comorbid or current critical condition
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Mesenchymal stem cells

    10 patients will be given mesenchymal stem cells at dose 2x10\^6 cells/kg MSCs on days 1 and day 7 (if needed) in addition to standard care

    Drug: Mesenchymal stem cells

  • Placebo comparator
    Placebo

    Only supportive care will be given to 10 patients

    Other: Placebo

Interventions

  • DrugMesenchymal stem cells

    1. Frozen MSCs will be resuspended in 100ml normal saline for immediate use and given intravenously. The patients should be pre-medicated to avoid allergic reactions to third party MSCs. Each patient in Experimental arm will be given 2 x 106 cells/kg will be administered on day 1,7 in addition to supportive care

    Also known as: MSCs

  • OtherPlacebo

    100 ml of normal saline will be given intravenously to control arm

06

What researchers measure

Primary outcomes

  1. Overall survival

    Assessment of Overall survival at 30 days post intervention

    Time frame: 30 days post intervention

Secondary outcomes

  1. Clinical improvement

    days required for oxygen support independence after intervention

    Time frame: 30 days

  2. Time of COVID19 PCR negativity

    PCR testing to check PCR negativity

    Time frame: day 1,3,7,10, 14

  3. Radiological improvement (day 15 and day 30 assessment)

    Computed tomography Chest assesment will be done to assess improvment in radiological findings of COVID-19

    Time frame: day 15 and day30

  4. days required to discharge from hospital

    number of days required for discharge from hospital

    Time frame: 30 days post admission

07

Study locations

1 of 1 sites recruiting
  • NIBMT
    Rawalpindi, Punjab 46000, Pakistan
    Recruiting
    • Xanab Akram · Contact03325346564
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2020 (actual). Primary completion is estimated for Aug 2020, 3 months after the start.

Of 359 non-industry phase 2 interventional studies under COVID-19, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's planned 3 months is below that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2020
First posted
Jun 23, 2020
StartActual
May 1, 2020
Primary completionEst.
Aug 30, 2020
CompletionEst.
Sep 30, 2020
Last update
Jun 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04444271
Lead sponsor
Dr. Zaineb Akram
Responsible party
Dr. Zaineb Akram (Research officer, National Institute of Blood and Marrow Transplant (NIBMT), Pakistan) — Sponsor-investigator
First posted
Jun 23, 2020
Start date
May 1, 2020
Primary completion
Aug 30, 2020 (estimated)
Completion
Sep 30, 2020 (estimated)
Last update
Jun 30, 2020

Study contacts

xanab akram
Contact
xanab.akram@gmail.com
03325346564
xanab akram
study chair · NIBMT

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion